Siegfried Holding AG (SFZN.SW) SIX

Currency In CHF

Key Executives

Name	Title	Pay	Year Born
Marcel Imwinkelried	Chief Executive Officer & Chief Operating Officer Drug Products ad interim	1.66M	1967
Beatrice Harder	Head Regulatory Affairs - Site Zofingen	0	N/A
Luca Dalla Torre	Chief Legal & Sustainability Officer	0	N/A
Florent Trouillet	Head Corporate Quality Systems - Global Quality Systems	0	N/A
John Jones	Head of Operations - Malta	0	N/A
Enno Schweinberger	Head Global Quality Management DS - Zofingen	0	N/A
Peter Stierli	Head of Corporate Communications	0	N/A
Olesia Silanteva	Chief Human Resources Officer	0	1982
Reto Suter	Chief Financial Officer	0	1971
Stefan Randl	Interim Chief Operating Officer Drug Substances & Chief Scientific Officer	0	N/A

Name

Title

Pay

Year Born

Marcel Imwinkelried

Chief Executive Officer & Chief Operating Officer Drug Products ad interim

1.66M

1967

Beatrice Harder

Head Regulatory Affairs - Site Zofingen

N/A

Luca Dalla Torre

Chief Legal & Sustainability Officer

N/A

Florent Trouillet

Head Corporate Quality Systems - Global Quality Systems

N/A

John Jones

Head of Operations - Malta

N/A

Enno Schweinberger

Head Global Quality Management DS - Zofingen

N/A

Peter Stierli

Head of Corporate Communications

N/A

Olesia Silanteva

Chief Human Resources Officer

1982

Reto Suter

Chief Financial Officer

1971

Stefan Randl

Interim Chief Operating Officer Drug Substances & Chief Scientific Officer

N/A

Description

Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis that manufactures custom APIs. The company also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition. In addition, it offers drug products, including steriles, which includes fill and finish in vials, ampoules, cartridges, and pre-filled syringes; ophthalmics, such as sterile ointments, gels, and suspensions and solutions; inhalation products, including capsules in medical devices for inhalation applications; oral solid dosage forms, which includes tablets and capsules; and viral vectors, such as AAV and lentiviruses for gene therapy. Further, the company provides technologies with chemistry capabilities, analytical services, formulation technologies, bridging technologies, containment technology, and cell and gene therapies. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.